CSS
SPRY icon

Cubist Systematic Strategies’s ARS Pharmaceuticals SPRY Stock Holding History

Cubist Systematic Strategies’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-77,162
Closed -$423K – 4235
2023
Q4 		$423K Buy
+77,162
New +$338K ﹤0.01% 2605
2023
Q2 		– Sell
-35,114
Closed -$229K – 4257
2023
Q1 		$229K Sell
35,114
-28,966
-45% -$223K ﹤0.01% 3162
2022
Q4 		$547K Buy
+64,080
New +$416K ﹤0.01% 2959
2022
Q3 		– Sell
-14,159
Closed -$60K – 4702
2022
Q2 		$60K Sell
14,159
-22,122
-61% -$77.1K ﹤0.01% 4068
2022
Q1 		$127K Sell
36,281
-8,293
-19% -$36.1K ﹤0.01% 3180
2021
Q4 		$297K Sell
44,574
-12,480
-22% -$101K ﹤0.01% 2806
2021
Q3 		$569K Buy
57,054
+56,981
+78,056% +$1.41M 0.01% 1946
2021
Q2 		$2K Buy
+73
New +$2.34K ﹤0.01% 2888

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's SPRY Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of ARS Pharmaceuticals (SPRY) in Q1 2024, closing a stake of 77,162 shares — an estimated $423K sold.

Cubist Systematic Strategies first reported a position in SPRY in Q2 2021 and held it in 8 quarters. The position peaked at $569K in Q3 2021. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining ARS Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 77,162 ARS Pharmaceuticals shares in Q1 2024, an estimated $423K.
  • Cubist Systematic Strategies first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Cubist Systematic Strategies's ARS Pharmaceuticals position peaked at $569K in Q3 2021.
  • 113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.